59285-7 |
Benzylpiperazine |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Benzylpiperazine [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
10 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59285-7 |
|
|
|
|
Both |
|
|
|
0 |
Benzylpiperazine Bld-mCnc |
|
|
|
N |
|
Addiction; Blood; BZP; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Level; Mass concentration; N-Benzylpiperazine; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59286-5 |
Benzylpiperazine |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Benzylpiperazine [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
10 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59286-5 |
|
|
|
|
Both |
|
|
|
0 |
Benzylpiperazine SerPl-mCnc |
|
|
|
N |
|
Addiction; BZP; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Level; Mass concentration; N-Benzylpiperazine; Pl; Plasma; Plsm; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59287-3 |
Benzylpiperazine |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Benzylpiperazine [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
10 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59287-3 |
|
|
|
|
Both |
|
|
|
0 |
Benzylpiperazine Ur-mCnc |
|
|
|
N |
|
Addiction; BZP; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Level; Mass concentration; N-Benzylpiperazine; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59288-1 |
Bisphenol A |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Bisphenol A [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
0.25 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59288-1 |
|
|
|
|
Both |
|
|
|
0 |
Bisphenol A Ur-mCnc |
|
|
|
N |
|
BPA; DRUG/TOXICOLOGY; Drugs; Endocrine disruptor; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59289-9 |
Iloperidone |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Iloperidone [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
0.25 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59289-9 |
|
|
|
|
Both |
|
|
|
0 |
Iloperidone Bld-mCnc |
|
|
|
N |
|
Blood; DRUG/TOXICOLOGY; Drugs; Fanapt; Fanapta; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood; Zomaril |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
5929-5 |
Candida albicans reaction wheal^3D post 50 ug Candida albicans ID |
Diam |
Skin |
Pt |
Qn |
|
|
ACTIVE |
Candida albicans reaction wheal [Diameter] --3 days post 50 ug Candida albicans intradermal |
|
MIN |
DefinitionDescription |
|
|
mm |
|
|
|
|
|
|
CHALSKIN |
|
5929-5 |
|
|
|
|
Observation |
|
|
|
0 |
Wheal 3D p 50ug C albicans Diam |
|
|
|
Y |
|
3D p 50ug C albicans; After; C albicans; Cand; Candidiasis; Dermatologic; Diameter; Epidermis; Identifier; Integument; Intradermal; m005; m5; mcg; Monilia; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; React; Rx wheal; Rxn; Skin test; SKIN TESTS; Skn; Thrush |
2.42 |
1.0b |
|
|
|
|
|
|
|
mm |
|
|
|
0 |
59290-7 |
Iloperidone |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Iloperidone [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
0.25 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59290-7 |
|
|
|
|
Both |
|
|
|
0 |
Iloperidone SerPl-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Fanapt; Fanapta; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Zomaril |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59291-5 |
Levamisole |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Levamisole [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
0.1 mcg/mL |
|
|
|
|
|
DRUG/TOX |
|
59291-5 |
|
|
|
|
Both |
|
|
|
0 |
Levamisole Bld-mCnc |
|
|
|
N |
|
Blood; Cocaine cutting agent; DRUG/TOXICOLOGY; Drugs; Ergamisole; Levasole; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.7 |
2.32 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
59292-3 |
Levamisole |
MCnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
Levamisole [Mass/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
0.1 mcg/mL |
|
|
|
|
|
DRUG/TOX |
|
59292-3 |
|
|
|
|
Both |
|
|
|
0 |
Levamisole Fld-mCnc |
|
|
|
N |
|
B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Cocaine cutting agent; DRUG/TOXICOLOGY; Drugs; Ergamisole; Fl; Fld; FLU; Fluid; Levasole; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.7 |
2.32 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
59293-1 |
Levamisole |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Levamisole [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
0.1 mcg/mL |
|
|
|
|
|
DRUG/TOX |
|
59293-1 |
|
|
|
|
Both |
|
|
|
0 |
Levamisole SerPl-mCnc |
|
|
|
N |
|
Cocaine cutting agent; DRUG/TOXICOLOGY; Drugs; Ergamisole; Levasole; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.32 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
59294-9 |
Levamisole |
MCnt |
Tiss |
Pt |
Qn |
|
|
ACTIVE |
Levamisole [Mass/mass] in Tissue |
|
MIN |
DefinitionDescription |
|
|
ug/g |
0.1 mcg/g |
|
|
|
|
|
DRUG/TOX |
|
59294-9 |
|
|
|
|
Both |
|
|
|
0 |
Levamisole Tiss-mCnt |
|
|
|
N |
|
Cocaine cutting agent; DRUG/TOXICOLOGY; Drugs; Ergamisole; Levasole; Mass content; Point in time; QNT; Quan; Quant; Quantitative; Random; Tissue; Tissue, unspecified |
2.7 |
2.32 |
|
|
|
|
|
|
|
ug/g |
|
|
Changed Property from 'MCnc' it fit the current LOINC model. |
0 |
59295-6 |
Levamisole |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Levamisole [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
0.1 mcg/mL |
|
|
|
|
|
DRUG/TOX |
|
59295-6 |
|
|
|
|
Both |
|
|
|
0 |
Levamisole Ur-mCnc |
|
|
|
N |
|
Cocaine cutting agent; DRUG/TOXICOLOGY; Drugs; Ergamisole; Levasole; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.7 |
2.32 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
59296-4 |
Lacosamide |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Lacosamide [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
0.5 mcg/mL |
|
|
|
|
|
DRUG/TOX |
|
59296-4 |
|
|
|
|
Both |
|
|
|
0 |
Lacosamide Bld-mCnc |
|
|
|
N |
|
Blood; DRUG/TOXICOLOGY; Drugs; Erlosamide; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Vimpat; WB; Whole blood |
2.73 |
2.32 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
59297-2 |
Lacosamide |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Lacosamide [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
0.5 mcg/mL |
|
|
|
|
|
DRUG/TOX |
|
59297-2 |
|
|
|
|
Both |
|
|
|
0 |
Lacosamide SerPl-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Erlosamide; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; UniversalLabOrders; Vimpat |
2.73 |
2.32 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
59298-0 |
Lacosamide |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Lacosamide [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
0.5 mcg/mL |
|
|
|
|
|
DRUG/TOX |
|
59298-0 |
|
|
|
|
Both |
|
|
|
0 |
Lacosamide Ur-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Erlosamide; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn; Vimpat |
2.7 |
2.32 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
59299-8 |
Desloratadine |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Desloratadine [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
1 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59299-8 |
|
|
|
|
Both |
|
|
|
0 |
Desloratadine Bld-mCnc |
|
|
|
N |
|
Blood; Claramax; Clarinex; Delot; Descarboethoxyloratadine; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; NeoClarinex; NeoClarityn; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
593-4 |
Legionella sp |
Prid |
XXX |
Pt |
Nom |
Organism specific culture |
|
ACTIVE |
Legionella sp identified in Specimen by Organism specific culture |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
593-4 |
|
Organism specific culture |
|
|
Both |
|
|
|
0 |
Legionella Spec Cult |
|
|
|
|
|
C&S; Cult; Cultures; ID; Identity or presence; Infectious Disease; InfectiousDisease; Legion; Legionela; Microbiology; Misc; Miscellaneous; Nominal; Other; Point in time; Random; Spec; species; spp; To be specified in another part of the message; UniversalLabOrders; Unspecified |
2.79 |
1 |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by the coll w SCT:The understanding is that the word "identified" refers to the property "PRID", its presence in the component is redundant to the property. Therefore it is better to remove "identified" from the component.; |
0 |
5930-3 |
Mumps reaction wheal^3D post 0.1 mL mumps ID |
Diam |
Skin |
Pt |
Qn |
|
|
ACTIVE |
Mumps reaction wheal [Diameter] --3 days post 0.1 mL mumps intradermal |
|
MIN |
DefinitionDescription |
|
|
mm |
|
|
|
|
|
|
CHALSKIN |
|
5930-3 |
|
|
|
|
Observation |
|
|
|
0 |
Wheal 3D p .1mL Mumps Diam |
|
|
|
Y |
|
3D p .1mL Mumps; After; Dermatologic; Diameter; Epidermis; Identifier; Integument; Intradermal; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; React; Rx wheal; Rxn; Skin test; SKIN TESTS; Skn |
2.26 |
1.0c |
|
|
|
|
|
|
|
mm |
|
|
|
0 |
59300-4 |
Desloratadine |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Desloratadine [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
1 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59300-4 |
|
|
|
|
Both |
|
|
|
0 |
Desloratadine SerPl-mCnc |
|
|
|
N |
|
Claramax; Clarinex; Delot; Descarboethoxyloratadine; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; NeoClarinex; NeoClarityn; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59301-2 |
Desloratadine |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Desloratadine [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
1 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59301-2 |
|
|
|
|
Both |
|
|
|
0 |
Desloratadine Ur-mCnc |
|
|
|
N |
|
Claramax; Clarinex; Delot; Descarboethoxyloratadine; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; NeoClarinex; NeoClarityn; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59302-0 |
Memantine |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Memantine [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
2 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59302-0 |
|
|
|
|
Both |
|
|
|
0 |
Memantine Bld-mCnc |
|
|
|
N |
|
Abixa; Akatinol; Axura; Blood; DRUG/TOXICOLOGY; Drugs; Ebixa; Level; Mass concentration; Memox; Namenda; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59303-8 |
Memantine |
MCnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
Memantine [Mass/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
2 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59303-8 |
|
|
|
|
Both |
|
|
|
0 |
Memantine Fld-mCnc |
|
|
|
N |
|
Abixa; Akatinol; Axura; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; DRUG/TOXICOLOGY; Drugs; Ebixa; Fl; Fld; FLU; Fluid; Level; Mass concentration; Memox; Namenda; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59304-6 |
Memantine |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Memantine [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
2 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59304-6 |
|
|
|
|
Both |
|
|
|
0 |
Memantine SerPl-mCnc |
|
|
|
N |
|
Abixa; Akatinol; Axura; DRUG/TOXICOLOGY; Drugs; Ebixa; Level; Mass concentration; Memox; Namenda; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59305-3 |
Memantine |
MCnt |
Tiss |
Pt |
Qn |
|
|
ACTIVE |
Memantine [Mass/mass] in Tissue |
|
MIN |
DefinitionDescription |
|
|
ng/g |
2 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59305-3 |
|
|
|
|
Both |
|
|
|
0 |
Memantine Tiss-mCnt |
|
|
|
N |
|
Abixa; Akatinol; Axura; DRUG/TOXICOLOGY; Drugs; Ebixa; Mass content; Memox; Namenda; Point in time; QNT; Quan; Quant; Quantitative; Random; Tissue; Tissue, unspecified |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
Changed Property from 'MCnc' it fit the current LOINC model. |
0 |
59306-1 |
Memantine |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Memantine [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
2 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59306-1 |
|
|
|
|
Both |
|
|
|
0 |
Memantine Ur-mCnc |
|
|
|
N |
|
Abixa; Akatinol; Axura; DRUG/TOXICOLOGY; Drugs; Ebixa; Level; Mass concentration; Memox; Namenda; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |